Investor Presentation

Shilpa Medicare Limited Corporate & Admin Office: “Shilpa House”, # 12-6-214/A-1, Hyderabad Road, Raichur – 584 135, Karnataka, India Tel: +91-8532-238704, Fax: +91-8532-238876 Email: info@vbshilpa.com, Web: www.vbshilpa.com CIN: L85110KA1987PLC008739 Date: 5 August 2026 Corporate Relationship Department National Stock Exchange of India Limited BSE Limited Exchange Plaza, 5" Floor, Phiroze Jeejeebhoy Towers, Plot No.C/1, G Block Dalal Street, Fort, Bandra Kurla Complex, Bandra (E) Mumbai-400 001 Mumbai-400 051 Scrip Code: BSE - 530549/ Stock Symbol: NSE – SHILPAMED Dear Sir/ Ma’am, Sub: Investor presentation of the Company for the quarter ended 30 June 2026 Ref: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 With reference to the captioned subject, the Investor Presentation for the quarter ended 30 June 2026, on Company Overview, Business highlights, financial performance and other updates is enclosed herewith for your consideration. A copy of this intimation is also being made available at: https://www.vbshilpa.com/investor-presentation.php This is for your information. Thanking you. For Shilpa Medicare Limited Ritu Tiwary Company Secretary & Compliance Officer Shilpa Medicare Ltd 1QFY27 Earnings Presentation Date: 5th August 2026 Safe Harbour Certain statements in this document may be forward - looking statements. Such forward looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Shilpa Medicare Limited (SML) will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances. Shilpa Medicare at Established in 1987, we have 35+ years track record a glance Existing Business Segments: API , Formulation, CDMO, Biologics Emerging Businesses: NDDS, ADC and Recombinant Human Albumin 10+ Regulatory approved manufacturing + R&D facilities (incl Analytical Lab) 400+ R&D Personnel 500+ Regulatory Filings across the world Worldwide presence in 50+ countries Revenue INR 469 crores (+43% YoY) 1QFY27 Financials EBITDA INR 139 crores (+42% YoY) Key operating verticals API Formulations Biologics 1QFY27 Revenue contribution ▪ Shilpa Pharma Lifesciences ▪ Shilpa Medicare ▪ Shilpa Biologicals Legal ▪ Shilpa Therapeutics ▪ Shilpa Biocare Entities ▪ FTF Pharma Areas of ▪ Oncology ▪ Tablets/Capsules ▪ NBE ▪ Non-Oncology ▪ Injectables ▪ Microbials Products Operation ▪ Payloads and Linkers ▪ Oral Dissolving Films ▪ Mammalian Products ▪ Peptides ▪ Transdermal patches ▪ CDMO ▪ Polymers ▪ CDMO ▪ ADCs ▪ GLP-1 ▪ CDMO API Includes others Management Commentary We begin FY27 on a strong note, with 1QFY27 reflecting healthy revenue growth of 43% (YoY) and EBITDA growth of 42% (YoY), with a robust margin of 30%, led by consistent improvement visible across our three key verticals. This performance reaffirms the operating discipline and strategic direction we have built over the past few years. Our approach continues to be anchored in building a differentiated, integrated organization — one that combines robust R&D, manufacturing capabilities, and a growing portfolio of novel and complex products. This integration continues to be a key differentiator, allowing us to capture value across the chain while deepening and widening our relations with global customers. The regulatory and manufacturing investments are now translating into tangible outcomes, and we expect this momentum to build further through the year as more of these initiatives mature and scale. Our collaborative approach to innovation continues to gain recognition, with partnerships forged with large global companies across our complex and novel product portfolio, reaffirming our position as a partner of choice for novel therapy development. Most recently, Gate2Brain became our fourth partnership for a novel asset, with Shilpa taking a stake in the company and stepping in as its integrated CMC, manufacturing and regulatory partner for G2B-002 — a BBB-penetrant, Orphan Drug-designated oncology asset for brain cancer. Alongside this operating momentum, our consistent and significant improvement in operating and financial performance over the past few years was recognized through a credit rating upgrade, with a category shift from A+ to AA-. This upgrade is a significant milestone and a strong external validation of the financial stability, prudence, and disciplined business practices that have underpinned our growth journey. Our capital efficiency continues to improve, with ROCE trending upwards, reflecting improvement in our operational momentum. With a strong pipeline, wider global network, and a sharpened strategic focus, we remain confident of delivering a stronger FY27. — Mr. Vishnukant Bhutada Managing Director Financial Performance 1Q FY27 – Financial Highlights Highest Quarterly Revenue and EBITDA 1Q FY27 (Consolidated) Revenue Break-up (INR crs) Particulars (INR cr) 1QFY27 1QFY26 YoY 4QFY26 QoQ Biologicals, Total Revenue 469 328 43% 439 7% Gross Profit 334 248 34% 297 13% GP Margin 71% 76% 68% Formulation, EBITDA 139 98 42% 121 15% 198 1Q FY27 API, 216 EBITDA Margin 30% 30% 28% 42% PAT 101 47 115% 87* 16% Adj. PAT Margin 22% 14% 20% Result commentary ▪ Delivered highest-ever quarterly revenue at INR 469 crs, a robust 43% increase on YoY basis; driven by growth across verticals ▪ Highest quarterly EBITDA at INR 139crs, growing 42% YoY; demonstrating strong operating leverage ▪ EBITDA Margins stood at 30% ▪ PAT came in at INR 101crs growing at ~115% YoY 4QFY26 PAT* - Adjusted for exceptional items All numbers are rounded off to nearest one Consolidated Performance (INR in Cr.) Revenues EBITDA and Margins 328 439 469 1QFY26 4QFY26 1QFY27 1QFY26 4QFY26 1QFY27 Operating PBT and Margins PAT and Margins 20% 22% 15% 14% 50 101 1QFY26 4QFY26*^ 1QFY27^ 1QFY26 4QFY26* 1QFY27 *Before Exceptional Items ^ Before profit from associates Financial Summary Adjusted ROCE^ Gross Block (INR crs) 17.4% 18.3% 15.0% 9.3% 2,281 2,328 1,997 3.4% 1,587 1,670 FY23 FY24 FY25 FY26 1QFY27* FY23 FY24 FY25 FY26 1QFY27 Net Debt to EBITDA (x) Net Capex (INR crs) 1.6 1.4 1.3 225 216 FY23 FY24 FY25 FY26 1QFY27* FY23 FY24 FY25 FY26 1QFY27 Credit rating upgraded with a category shift from A+ to AA-, driven by strengthening balance sheet and improving return ratios ^ Adjusted ROCE excluding investments made in potential high growth biologics & NBE business 9 *Note – 1QFY27 Numbers are on TTM basis API Business API – Growth driven by core portfolio (INR in Cr.) ▪ Revenue growth came in at ~15% Incl. Captive 226 259 260 YoY for the quarter ▪ The captive business continued to 36 36 grow consistently, underpinned 17 by steady internal demand from the FDF vertical, reinforcing its role as a long-term revenue contributor ▪ Non-Captive portfolio grew by 223 224 209 ~15% YoY on the back of broad- based growth, and primarily driven by Specialty CDMO ▪ The Specialty CDMO division continues to see strong traction, driven by new client acquisitions API Specialty CDMO* in developed markets 1QFY26 4QFY26 1QFY27 * Specialty CDMO includes revenue from API CDMO, Peptide and Polymer verticals 11 API – Ongoing Developments API Molecules Specialty CMDO ▪ One program received US FDA approval ▪ 20+ products across the Onco and Non-Onco API portfolio ▪ Strong order book in Peptide segment provides healthy are currently under development, with validations for all ▪ Successfully completed 2 new audits by global MNC revenue visibility for FY27 products progressing on track customers ▪ Peptide expansion underway, set to add one of the ▪ Onco portfolio revamped with 15+ new APIs added to the ▪ Secured 2 new late-stage business opportunities with lar [Showing first 8,000 characters — download PDF for full document]